187 related articles for article (PubMed ID: 27329245)
1. Stimulation of cellular senescent processes, including secretory phenotypes and anti-oxidant responses, after androgen deprivation therapy in human prostate cancer.
Kawata H; Kamiakito T; Nakaya T; Komatsubara M; Komatsu K; Morita T; Nagao Y; Tanaka A
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):219-227. PubMed ID: 27329245
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo.
Ewald JA; Desotelle JA; Church DR; Yang B; Huang W; Laurila TA; Jarrard DF
Prostate; 2013 Mar; 73(4):337-45. PubMed ID: 22911222
[TBL] [Abstract][Full Text] [Related]
3. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U
Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
[TBL] [Abstract][Full Text] [Related]
4. Intra-prostatic androgen levels during various androgen-blockade regimens.
Nishiyama T
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
Singer EA; Golijanin DJ; Messing EM
Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
[TBL] [Abstract][Full Text] [Related]
6. Hyaluronan-mediated motility receptor (RHAMM) immunohistochemical expression and androgen deprivation in normal peritumoral, hyperplasic and neoplastic prostate tissue.
Korkes F; de Castro MG; de Cassio Zequi S; Nardi L; Del Giglio A; de Lima Pompeo AC
BJU Int; 2014 May; 113(5):822-9. PubMed ID: 24053431
[TBL] [Abstract][Full Text] [Related]
7. The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells.
Esmaeili M; Jennek S; Ludwig S; Klitzsch A; Kraft F; Melle C; Baniahmad A
J Mol Cell Biol; 2016 Jun; 8(3):207-20. PubMed ID: 26993046
[TBL] [Abstract][Full Text] [Related]
8. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
[TBL] [Abstract][Full Text] [Related]
9. Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy.
Shibata Y; Suzuki K; Arai S; Miyoshi Y; Umemoto S; Masumori N; Kamiya N; Ichikawa T; Kitagawa Y; Mizokami A; Sugimura Y; Nonomura N; Sakai H; Honma S; Kubota Y
Andrology; 2013 May; 1(3):505-11. PubMed ID: 23444052
[TBL] [Abstract][Full Text] [Related]
10. Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2.
Pernicová Z; Slabáková E; Kharaishvili G; Bouchal J; Král M; Kunická Z; Machala M; Kozubík A; Souček K
Neoplasia; 2011 Jun; 13(6):526-36. PubMed ID: 21677876
[TBL] [Abstract][Full Text] [Related]
11. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
[TBL] [Abstract][Full Text] [Related]
13. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
Mostaghel EA; Page ST; Lin DW; Fazli L; Coleman IM; True LD; Knudsen B; Hess DL; Nelson CC; Matsumoto AM; Bremner WJ; Gleave ME; Nelson PS
Cancer Res; 2007 May; 67(10):5033-41. PubMed ID: 17510436
[TBL] [Abstract][Full Text] [Related]
14. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.
Shiota M; Yokomizo A; Naito S
Free Radic Biol Med; 2011 Oct; 51(7):1320-8. PubMed ID: 21820046
[TBL] [Abstract][Full Text] [Related]
15. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation.
Nelson EC; Cambio AJ; Yang JC; Lara PN; Evans CP
Nat Clin Pract Urol; 2007 Feb; 4(2):82-94. PubMed ID: 17287869
[TBL] [Abstract][Full Text] [Related]
16. [Correlation between the expression of Pim-1 and androgen-deprivation therapy for prostate cancer].
Wang J; Quan CY; Chang WL; Shang ZQ; Jiang N; Li B; Niu YJ
Zhonghua Nan Ke Xue; 2015 Sep; 21(9):775-81. PubMed ID: 26552208
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.
Wright GL; Grob BM; Haley C; Grossman K; Newhall K; Petrylak D; Troyer J; Konchuba A; Schellhammer PF; Moriarty R
Urology; 1996 Aug; 48(2):326-34. PubMed ID: 8753752
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation modulates gene expression profile along prostate cancer progression.
Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
[TBL] [Abstract][Full Text] [Related]
19. The activation of OR51E1 causes growth suppression of human prostate cancer cells.
Maßberg D; Jovancevic N; Offermann A; Simon A; Baniahmad A; Perner S; Pungsrinont T; Luko K; Philippou S; Ubrig B; Heiland M; Weber L; Altmüller J; Becker C; Gisselmann G; Gelis L; Hatt H
Oncotarget; 2016 Jul; 7(30):48231-48249. PubMed ID: 27374083
[TBL] [Abstract][Full Text] [Related]
20. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
